There’s always this voice in the back of my head that always cautions me that all that glitters is not gold. After being heralded as the next savior in weight loss by the media, the GLP-1 Agonists/GIP agonists have come under more scrutiny lately in the news. A...
A new SGLT2i is now on the market, promoting a new option for diabetes management. Bexagliflozin (Brenzavvy) got FDA approval in January of this year adding it to the list of SGLT2 inhibitors. With a few already on the scene, it bears the question, is bexagliflozin...
It is theorized that patients who are taking a GLP-1 agonist are at a greater risk for pancreatitis due to the medication causing an increase in stimulation of GLP-1 receptors located in the pancreas. This could lead to an overgrowth or overactivation of pancreatic...
Tirzepatide is a newer medication that is likely to get significant use in Type 2 diabetes and weight management. With the help of a wonderful pharmacy student, we previously did a tirzepatide clinical breakdown which you can find here. Tirzepatide avoids many drug...
I know some folks out there really like crossword puzzles, so I figured why not combine a little fun with a little pharmacology education? I’ve created a free pharmacology crossword puzzle that you should be able to work through below. I didn’t make it...
